These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2005-002716-16 A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS 2008-04-30 due-trials
Completed, but no date 2007-001609-81 Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer bad-data
Not reported 2007-005737-11 Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma 2012-08-22 due-trials
Completed, report not yet due 2007-007241-12 A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER 2011-02-26 not-yet-due
Listed as ongoing, but also has a completion date 2009-013002-13 A prospective non-randomized study of 131I-L19SIP Radioimmunotherapy (RIT) in combination with Whole Brain Radiation Therapy (WBRT) in patients with multiple brain metastases from solid tumors 2012-10-01 bad-data
Not reported 2009-014799-23 A phase II study of intratumoral application of L19IL2 in patients with stage III/IV melanoma 2013-08-28 due-trials
Not reported 2012-001991-13 A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions. 2015-05-26 due-trials
Listed as ongoing, but also has a completion date 2012-004018-33 A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma. 2017-12-15 bad-data
Completed, but no date 2012-004495-19 A Phase I/II Dose Escalation study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine for patients with metastatic melanoma. bad-data
Ongoing 2013-005418-37 A multicenter, randomized, double-blind, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 (Dekavil) administered subcutaneously to patients w... not-yet-due
Ongoing 2014-001949-25 A Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Rituximab in relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not-yet-due
Ongoing 2015-002549-72 A Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage IIIB a... not-yet-due
Ongoing 2016-003239-38 A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients ... not-yet-due